These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

513 related items for PubMed ID: 29111028

  • 1. CSF biomarkers β-amyloid, tau proteins and a-synuclein in the differential diagnosis of Parkinson-plus syndromes.
    Constantinides VC, Paraskevas GP, Emmanouilidou E, Petropoulou O, Bougea A, Vekrellis K, Evdokimidis I, Stamboulis E, Kapaki E.
    J Neurol Sci; 2017 Nov 15; 382():91-95. PubMed ID: 29111028
    [Abstract] [Full Text] [Related]

  • 2. Differential role of CSF fatty acid binding protein 3, α-synuclein, and Alzheimer's disease core biomarkers in Lewy body disorders and Alzheimer's dementia.
    Chiasserini D, Biscetti L, Eusebi P, Salvadori N, Frattini G, Simoni S, De Roeck N, Tambasco N, Stoops E, Vanderstichele H, Engelborghs S, Mollenhauer B, Calabresi P, Parnetti L.
    Alzheimers Res Ther; 2017 Jul 28; 9(1):52. PubMed ID: 28750675
    [Abstract] [Full Text] [Related]

  • 3. Accuracy of a panel of 5 cerebrospinal fluid biomarkers in the differential diagnosis of patients with dementia and/or parkinsonian disorders.
    Hall S, Öhrfelt A, Constantinescu R, Andreasson U, Surova Y, Bostrom F, Nilsson C, Håkan W, Decraemer H, Någga K, Minthon L, Londos E, Vanmechelen E, Holmberg B, Zetterberg H, Blennow K, Hansson O.
    Arch Neurol; 2012 Nov 28; 69(11):1445-52. PubMed ID: 22925882
    [Abstract] [Full Text] [Related]

  • 4. Clinical value of CSF amyloid-beta-42 and tau proteins in Progressive Supranuclear Palsy.
    Schirinzi T, Sancesario GM, Di Lazzaro G, Scalise S, Colona VL, Imbriani P, Mercuri NB, Bernardini S, Lang AE, Pisani A.
    J Neural Transm (Vienna); 2018 Sep 28; 125(9):1373-1379. PubMed ID: 29948175
    [Abstract] [Full Text] [Related]

  • 5. Tau/α-synuclein ratio and inflammatory proteins in Parkinson's disease: An exploratory study.
    Delgado-Alvarado M, Gago B, Gorostidi A, Jiménez-Urbieta H, Dacosta-Aguayo R, Navalpotro-Gómez I, Ruiz-Martínez J, Bergareche A, Martí-Massó JF, Martínez-Lage P, Izagirre A, Rodríguez-Oroz MC.
    Mov Disord; 2017 Jul 28; 32(7):1066-1073. PubMed ID: 28548309
    [Abstract] [Full Text] [Related]

  • 6. Amyloid-β and α-synuclein cerebrospinal fluid biomarkers and cognition in early Parkinson's disease.
    Stav AL, Aarsland D, Johansen KK, Hessen E, Auning E, Fladby T.
    Parkinsonism Relat Disord; 2015 Jul 28; 21(7):758-64. PubMed ID: 25971633
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Decreased beta-amyloid peptide42 in cerebrospinal fluid of patients with progressive supranuclear palsy and corticobasal degeneration.
    Noguchi M, Yoshita M, Matsumoto Y, Ono K, Iwasa K, Yamada M.
    J Neurol Sci; 2005 Oct 15; 237(1-2):61-5. PubMed ID: 15992827
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Cerebrospinal fluid levels of alpha-synuclein, amyloid β, tau, phosphorylated tau, and neuron-specific enolase in patients with Parkinson's disease, dementia with Lewy bodies or other neurological disorders: Their relationships with cognition and nuclear medicine imaging findings.
    Katayama T, Sawada J, Kikuchi-Takeguchi S, Kano K, Takahashi K, Saito T, Okizaki A, Hasebe N.
    Neurosci Lett; 2020 Jan 10; 715():134564. PubMed ID: 31733322
    [Abstract] [Full Text] [Related]

  • 12. Cerebrospinal fluid concentrations of inflammatory markers in Parkinson's disease and atypical parkinsonian disorders.
    Hall S, Janelidze S, Surova Y, Widner H, Zetterberg H, Hansson O.
    Sci Rep; 2018 Sep 05; 8(1):13276. PubMed ID: 30185816
    [Abstract] [Full Text] [Related]

  • 13. α-Synuclein and tau concentrations in cerebrospinal fluid of patients presenting with parkinsonism: a cohort study.
    Mollenhauer B, Locascio JJ, Schulz-Schaeffer W, Sixel-Döring F, Trenkwalder C, Schlossmacher MG.
    Lancet Neurol; 2011 Mar 05; 10(3):230-40. PubMed ID: 21317042
    [Abstract] [Full Text] [Related]

  • 14. Cerebrospinal fluid biomarkers for Parkinson disease diagnosis and progression.
    Shi M, Bradner J, Hancock AM, Chung KA, Quinn JF, Peskind ER, Galasko D, Jankovic J, Zabetian CP, Kim HM, Leverenz JB, Montine TJ, Ginghina C, Kang UJ, Cain KC, Wang Y, Aasly J, Goldstein D, Zhang J.
    Ann Neurol; 2011 Mar 05; 69(3):570-80. PubMed ID: 21400565
    [Abstract] [Full Text] [Related]

  • 15. Cerebrospinal fluid Abeta42 is reduced in multiple system atrophy but normal in Parkinson's disease and progressive supranuclear palsy.
    Holmberg B, Johnels B, Blennow K, Rosengren L.
    Mov Disord; 2003 Feb 05; 18(2):186-90. PubMed ID: 12539213
    [Abstract] [Full Text] [Related]

  • 16. Alpha-Synuclein Protofibrils in Cerebrospinal Fluid: A Potential Biomarker for Parkinson's Disease.
    von Euler Chelpin M, Söderberg L, Fälting J, Möller C, Giorgetti M, Constantinescu R, Blennow K, Zetterberg H, Höglund K.
    J Parkinsons Dis; 2020 Feb 05; 10(4):1429-1442. PubMed ID: 33016895
    [Abstract] [Full Text] [Related]

  • 17. High discriminatory ability of peripheral and CFSF biomarkers in Lewy body diseases.
    Bougea A, Stefanis L, Emmanouilidou E, Vekrelis K, Kapaki E.
    J Neural Transm (Vienna); 2020 Mar 05; 127(3):311-322. PubMed ID: 31912280
    [Abstract] [Full Text] [Related]

  • 18. Cerebrospinal fluid Tau/α-synuclein ratio in Parkinson's disease and degenerative dementias.
    Parnetti L, Chiasserini D, Bellomo G, Giannandrea D, De Carlo C, Qureshi MM, Ardah MT, Varghese S, Bonanni L, Borroni B, Tambasco N, Eusebi P, Rossi A, Onofrj M, Padovani A, Calabresi P, El-Agnaf O.
    Mov Disord; 2011 Jul 05; 26(8):1428-35. PubMed ID: 21469206
    [Abstract] [Full Text] [Related]

  • 19. CSF α-synuclein and UCH-L1 levels in Parkinson's disease and atypical parkinsonian disorders.
    Mondello S, Constantinescu R, Zetterberg H, Andreasson U, Holmberg B, Jeromin A.
    Parkinsonism Relat Disord; 2014 Apr 05; 20(4):382-7. PubMed ID: 24507721
    [Abstract] [Full Text] [Related]

  • 20. Association of cerebrospinal fluid β-amyloid 1-42, T-tau, P-tau181, and α-synuclein levels with clinical features of drug-naive patients with early Parkinson disease.
    Kang JH, Irwin DJ, Chen-Plotkin AS, Siderowf A, Caspell C, Coffey CS, Waligórska T, Taylor P, Pan S, Frasier M, Marek K, Kieburtz K, Jennings D, Simuni T, Tanner CM, Singleton A, Toga AW, Chowdhury S, Mollenhauer B, Trojanowski JQ, Shaw LM, Parkinson's Progression Markers Initiative.
    JAMA Neurol; 2013 Oct 05; 70(10):1277-87. PubMed ID: 23979011
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 26.